Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Fontan-palliated subjects
NCT03153137Phase 3Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2017
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of macitentan in congenital heart disease (CHD), Fontan circulation, sponsored by Actelion Pharmaceuticals Ltd. Started Aug 2017; status: completed.
02
Drugs
macitentan
03
Conditions
congenital heart disease (CHD)Fontan circulation
Beyond the preview
Go deeper on NCT03153137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03153137.